Navigation Links
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Date:7/23/2008

cutive business days by that time.

The NASDAQ Staff Determination letter states that historically, Panels have generally viewed a reverse stock split implemented within 30 to 60 days as the only definitive plan acceptable to resolve a bid price deficiency, but that recently the authority of Panels to grant additional time to companies was modified so that a Panel could allow up to 180 calendar days from the date of the Staff Determination letter, if the Panel deems it appropriate. The letter notes that the company may wish to consider presenting a plan that includes a discussion of the events that it believes will enable it to regain compliance in this time frame and a commitment to effect a reverse stock split, if necessary. However, there can be no assurance that the Panel will grant Peregrine's request for continued listing on the NASDAQ Capital Market.

As announced on July 25, 2007, Peregrine received a letter from NASDAQ advising that the bid price of the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 4310(c)(4) for the previous 30 consecutive business days. In accordance with NASDAQ Marketplace Rule 4310(c)(4), the company was provided 180 calendar days and granted an additional 180-day-extension period, or until July 21, 2008, to regain compliance with the minimum bid price requirement.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc.

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... nanotechnology company developing products and licensing opportunities in ... and biotechnology research and development tools businesses, announced ... development and manufacturing agreement with EV Group, a ...
... properties, carbon nanotubes are attractive building blocks ... logic devices, and memory elements. However, ... of individual carbon nanotubes and the nanotube-devices, ... commercial use. Now, researchers at Northwestern ...
... Calif., Dec. 7, 2010 California-based StemCyte, Inc. ... www.StemCyte.com , a comprehensive resource on cord blood ... an effort to provide the most comprehensive source ... StemCyte,s new website includes extensive information for customers, ...
Cached Biology Technology:Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5Using new materials to make more reliable nanoelectromechanical systems 2StemCyte Launches New Website 2
(Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
(Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... NEW YORK (July 24, 2009) -- A large attack on ... than a million people, necessitating their treatment with powerful antibiotics. ... to be effective, quick detection and treatment are essential, and ... ill people. The results of a computer simulation study ...
... GALVESTON, Texas Researchers at the University of Texas ... to gain weight while using depot medroxyprogesterone acetate, more commonly ... dispel the myth that all women who use DMPA will ... DMPA users whose weight increased by 5 percent within ...
... Union for the Conservation of Nature (IUCN),s Red List ... of species around the planet, and according to these ... endangered. However, research carried out recently by Jos Luis ... scientific protocol designed to identify threatened plants and animals. ...
Cached Biology News:Early detection and quick response are key to defense against anthrax attack 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2Red List overlooks island species 2Red List overlooks island species 3
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Pendrin (H-195)...
Request Info...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: